These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33235995)

  • 1. Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma.
    Ma S; Rudra S; Campian JL; Dahiya S; Dunn GP; Johanns T; Goldstein M; Kim AH; Huang J
    Neurooncol Adv; 2020; 2(1):vdaa126. PubMed ID: 33235995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
    Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
    Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
    Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
    Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature.
    Lu VM; O'Connor KP; Shah AH; Eichberg DG; Luther EM; Komotar RJ; Ivan ME
    J Neurooncol; 2020 Jun; 148(2):221-229. PubMed ID: 32385699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH wild-type lower-grade gliomas with glioblastoma molecular features: a systematic review and meta-analysis.
    Nakasu S; Deguchi S; Nakasu Y
    Brain Tumor Pathol; 2023 Jul; 40(3):143-157. PubMed ID: 37212969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastoma.
    Funakoshi Y; Hata N; Takigawa K; Arita H; Kuga D; Hatae R; Sangatsuda Y; Fujioka Y; Sako A; Umehara T; Yoshitake T; Togao O; Hiwatashi A; Yoshimoto K; Iwaki T; Mizoguchi M
    Cancer Med; 2021 May; 10(10):3177-3187. PubMed ID: 33838014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of
    Dono A; Ramesh AV; Wang E; Shah M; Tandon N; Ballester LY; Esquenazi Y
    Neurooncol Adv; 2021; 3(1):vdab050. PubMed ID: 34131647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study.
    Ramos-Fresnedo A; Pullen MW; Perez-Vega C; Domingo RA; Akinduro OO; Almeida JP; Suarez-Meade P; Marenco-Hillembrand L; Jentoft ME; Bendok BR; Trifiletti DM; Chaichana KL; Porter AB; Quiñones-Hinojosa A; Burns TC; Kizilbash SH; Middlebrooks EH; Sherman WJ
    J Neurooncol; 2022 Mar; 157(1):177-185. PubMed ID: 35175545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular landscape of IDH-wild type, pTERT-wild type adult glioblastomas.
    Liu EM; Shi ZF; Li KK; Malta TM; Chung NY; Chen H; Chan JY; Poon MF; Kwan JS; Chan DT; Noushmehr H; Mao Y; Ng HK
    Brain Pathol; 2022 Nov; 32(6):e13107. PubMed ID: 35815721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
    Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
    J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts.
    Galbraith K; Kumar A; Abdullah KG; Walker JM; Adams SH; Prior T; Dimentberg R; Henderson FC; Mirchia K; Sathe AA; Viapiano MS; Chin LS; Corona RJ; Hatanpaa KJ; Snuderl M; Xing C; Brem S; Richardson TE
    J Neuropathol Exp Neurol; 2020 Aug; 79(8):843-854. PubMed ID: 32647886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of new molecular criteria on diagnosis and survival of adult glioma patients.
    Mortensen D; Ulhøi BP; Lukacova S; Alsner J; Stougaard M; Nyengaard JR
    IBRO Neurosci Rep; 2022 Dec; 13():299-305. PubMed ID: 36204252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Characterization of "True" Low-Grade IDH-Wildtype Astrocytomas.
    Richardson TE; Hatanpaa KJ; Walker JM
    J Neuropathol Exp Neurol; 2021 Apr; 80(5):431-435. PubMed ID: 33829259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
    Tesileanu CMS; Dirven L; Wijnenga MMJ; Koekkoek JAF; Vincent AJPE; Dubbink HJ; Atmodimedjo PN; Kros JM; van Duinen SG; Smits M; Taphoorn MJB; French PJ; van den Bent MJ
    Neuro Oncol; 2020 Apr; 22(4):515-523. PubMed ID: 31637414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline.
    Velázquez Vega JE; Brat DJ; Ryken TC; Olson JJ
    J Neurooncol; 2020 Nov; 150(2):143-164. PubMed ID: 33215342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
    Yang RR; Shi ZF; Zhang ZY; Chan AK; Aibaidula A; Wang WW; Kwan JSH; Poon WS; Chen H; Li WC; Chung NY; Punchhi G; Chu WC; Chan IS; Liu XZ; Mao Y; Li KK; Ng HK
    Brain Pathol; 2020 May; 30(3):541-553. PubMed ID: 31733156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular landscape of pediatric type IDH wildtype, H3 wildtype hemispheric glioblastomas.
    Hong L; Shi ZF; Li KK; Wang WW; Yang RR; Kwan JS; Chen H; Li FC; Liu XZ; Chan DT; Li WC; Zhang ZY; Mao Y; Ng HK
    Lab Invest; 2022 Jul; 102(7):731-740. PubMed ID: 35332262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological and Molecular Characteristics of
    Bae H; Lee B; Hwang S; Lee J; Kim HS; Suh YL
    Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38255255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isocitrate Dehydrogenase 1/2 Wildtype Adult Astrocytoma with WHO Grade 2/3 Histological Features: Molecular Re-Classification, Prognostic Factors, Clinical Outcomes.
    Gupta M; Anjari M; Brandner S; Fersht N; Wilson E; Thust S; Kosmin M
    Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.